An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results
- PMID: 20936135
- PMCID: PMC2947816
- DOI: 10.1155/2010/347402
An International, Web-Based, Prospective Cohort Study to Determine Whether the Use of ACE Inhibitors prior to the Onset of Scleroderma Renal Crisis Is Associated with Worse Outcomes-Methodology and Preliminary Results
Abstract
Background. To describe the methodology of a study designed to determine whether systemic sclerosis (SSc) patients with incident scleroderma renal crisis (SRC) on angiotensin converting enzyme (ACE) inhibitors prior to the onset of SRC have worse outcomes. Methods. Prospective, international cohort study of SRC subjects identified through an ongoing web-based survey. Every second Friday afternoon, an e-mail was sent to 589 participating physicians to identify new cases of SRC. Death or dialysis at one year after the onset of SRC will be compared in patients exposed or not to ACE inhibitors prior to the onset of SRC. Results. Fifteen months after the start of the survey, we had identified 76 incident cases of SRC. Of these, 66 (87%) had a hypertensive SRC and 10 (13%) a normotensive SRC. Twenty-two percent (22%) of the patients were on an ACE inhibitor immediately prior to the onset of the SRC. To date, we have collected one-year follow-up data on approximately 1/3 of the cohort. Of these, over 50% have died or remain on dialysis at one year. Conclusion. An international, web-based cohort study design is a feasible method of recruiting a substantial number of patients to study an infrequent vascular manifestation of SSc.
Figures
Similar articles
-
Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey.Semin Arthritis Rheum. 2014 Apr;43(5):666-72. doi: 10.1016/j.semarthrit.2013.09.008. Epub 2013 Oct 7. Semin Arthritis Rheum. 2014. PMID: 24176729
-
Angiotensin-converting enzyme inhibitors prior to scleroderma renal crisis in systemic sclerosis: A systematic review and meta-analysis.J Clin Pharm Ther. 2022 Jun;47(6):722-731. doi: 10.1111/jcpt.13621. Epub 2022 Mar 1. J Clin Pharm Ther. 2022. PMID: 35233779 Review.
-
Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.Arthritis Rheum. 2002 Nov;46(11):2983-9. doi: 10.1002/art.10589. Arthritis Rheum. 2002. PMID: 12428241 Clinical Trial.
-
Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment.Intern Med J. 2003 May-Jun;33(5-6):216-20. doi: 10.1046/j.1445-5994.2003.00358.x. Intern Med J. 2003. PMID: 12752889
-
Scleroderma renal crisis.Semin Arthritis Rheum. 2015 Jun;44(6):687-94. doi: 10.1016/j.semarthrit.2014.12.001. Epub 2014 Dec 11. Semin Arthritis Rheum. 2015. PMID: 25613774 Review.
Cited by
-
Points to consider in renal involvement in systemic sclerosis.Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v49-v52. doi: 10.1093/rheumatology/kex201. Rheumatology (Oxford). 2017. PMID: 28992172 Free PMC article. Review.
-
Scleroderma renal crisis and renal involvement in systemic sclerosis.Nat Rev Nephrol. 2016 Nov;12(11):678-691. doi: 10.1038/nrneph.2016.124. Epub 2016 Sep 19. Nat Rev Nephrol. 2016. PMID: 27641135 Review.
-
Old medications and new targeted therapies in systemic sclerosis.Rheumatology (Oxford). 2015 Nov;54(11):1944-53. doi: 10.1093/rheumatology/keu285. Epub 2014 Jul 26. Rheumatology (Oxford). 2015. PMID: 25065013 Free PMC article. Review.
-
[Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].Z Rheumatol. 2013 Dec;72(10):960-9. doi: 10.1007/s00393-013-1270-2. Z Rheumatol. 2013. PMID: 24337198 Review. German.
References
-
- Steen VD. Scleroderma renal crisis. Rheumatic Disease Clinics of North America. 2003;29(2):315–333. - PubMed
-
- Steen VD, Medsger TA., Jr. Long-term outcomes of scleroderma renal crisis. Annals of Internal Medicine. 2000;133(8):600–603. - PubMed
-
- Denton CP, Black CM. Scleroderma—clinical and pathological advances. Best Practice and Research. 2004;18(3):271–290. - PubMed
-
- Steen VD, Medsger TA, Jr., Osial TA, Jr., Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. The American Journal of Medicine. 1984;76(5):779–786. - PubMed
-
- Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM—Monthly Journal of the Association of Physicians. 2007;100(8):485–494. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
